Get started
Author

Joana M Parreira

Observed names: J Parreira, J. Parreira, Joana M. Parreira, Joana Maria Parreira, Joana Parreira, Parreira, Joana
ORCID: 0009-0000-7134-2057
Observed ORCID: 0009-0000-7134-2057
OpenAlex ID: A5001781183
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review
2022 · Andrew Davies, Arnon P Kater, et al. · Future Oncology · 46
Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)
2016 · Pieter Sonneveld, Meral Beksac, et al. · Blood · 35
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
2023 · Matthew Matasar, Nancy L. Bartlett, et al. · Clinical Lymphoma Myeloma & Leukemia · 30
PDF
Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies
2021 · Thomas D. Rodgers, Carla Casulo, et al. · Oncology and Therapy · 19
PDF
Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy
2023 · Sarah F. McGough, Natasha Shamas, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 15
Hereditary breast cancer and ancestry in the Madeira archipelago: an exploratory study
2021 · Isália Miguel, Fátima Rodrigues, et al. · ecancermedicalscience · 14
PDF
NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL
2024 · Ehsan Tabari, Alexander F. Lovejoy, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 8
Men seeking counselling in a Breast Cancer Risk Evaluation Clinic
2018 · Ana Catarina Freitas, Ana Opinião, et al. · ecancermedicalscience · 8
PDF
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis
2023 · Miguel A. Canales, Thomas A. Buchholz, et al. · HemaSphere · 7
An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy
2022 · Sarah F. McGough, Natasha Shamas, et al. · Blood · 7
Germline Variants in DNA Interstrand-Cross Link Repair Genes May Contribute to Increased Susceptibility for Serrated Polyposis Syndrome
2024 · Patrícia Silva, Inês Francisco, et al. · International Journal of Molecular Sciences · 6
PDF
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation
2021 · Emmanuel Bachy, Kaspar Rufibach, et al. · Advances in Therapy · 6
PDF
Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma
2019 · Ehsan Tabari, Alexander F Lovejoy, et al. · Blood · 5
Obinutuzumab Can Be Administered as a 90‐minute Short‐duration Infusion (sdi) in Patients With Previously Untreated Follicular Lymphoma: Gazelle End of Induction Analysis
2021 · K. Hübel, T. A. Buchholz, et al. · Hematological Oncology · 2
PDF
Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.
2021 · Miguel Angel A. Canales Albendea, Thomas A. Buchholz, et al. · Journal of Clinical Oncology · 2
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide
2020 · Barbara Gamberi, Christian Berthou, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PDF
Abstract P6-08-17: When BRCA2-breast cancer is more prevalent than BRCA1-breast cancer: Prospective follow-up data from a multidisciplinary program
2020 · Catarina Bexiga, Priscila Nejo, et al. · Cancer Research · 2
Final efficacy results of the real-life ambispective urban study on frontline obinutuzumab-based immunochemotherapy for advanced follicular lymphoma
2025 · Antonio Pinto, Marco Caltagirone, et al. · Blood · 1
PDF
Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma
2021 · Peter Trask, Jaisson Bortolini, et al. · Blood · 1
Biliary tract cancers in Portuguese families with BRCA gene mutation: A retrospective study
2019 · P. Pereira, I. Oliveira, et al. · Annals of Oncology · 1
Does melanoma or other skin cancers belong to the BRCA2 phenotype?
2017 · R. Vitorino, F. Vaz, et al. · Annals of Oncology · 1
PDF
Men seeking counselling in a Breast Cancer Evaluation Clinic: fifteen years experience of a multidisciplinary program.
2016 · Ana Catarina Freitas, Ana Opiniao, et al. · Journal of Clinical Oncology · 1
1906 Management of BRCA 1/2 mutation carriers: 14 years of a multidisciplinary program
2015 · G. Rocha, A. Luís, et al. · European Journal of Cancer · 1
Clonal Hypereosinophilia with ETV6 Rearrangement Evolving to T-Cell Lymphoblastic Lymphoma: A Case Report and Review of the Literature
2013 · Filipa Moita, Isabel Bogalho, et al. · Case Reports in Hematology · 1
PDF
Obesity and Tolerance to Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Cohort Study
2026 · Madalena Silveira Machado, Madalena P. Santos, et al. · Cancers
PDF
Works count: 48
Citation count: 222
H-index: 8
I10-index: 6
Year
Topic
Type